NCT07275788招募中1 期
An Exploratory Study of REGEND003 Kidney Progenitor Cells on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Regend Therapeutics1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2026年1月8日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Adverse Event (AE) associated with the Cell Therapy
研究概览
简要总结
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged 30 to 75 years at the time of signing the informed consent form;
- •Diagnosed with Type 2 Diabetes Mellitus for at least 1 year;
- •Diagnosed with Chronic Kidney Disease (CKD);
- •Voluntarily sign the informed consent form, be able to cooperate in completing study-related procedures and examinations, capable of adequately recording or describing changes in their condition, and demonstrate strong compliance.
排除标准
- •Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);
- •At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test.
- •Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.
- •Presence of a current or prior history of malignant tumor at screening (with the exception of those with disease-free survival for more than 2 years, or malignancies deemed to be of low aggressiveness as assessed by the investigator).
- •Patients with Type 1 Diabetes Mellitus;
- •Patients undergoing regular hemodialysis or peritoneal dialysis;
- •Presence of severe acute complications of diabetes or CKD requiring hospitalization within 2 weeks prior to screening;
- •Presence of more than one episode of hypoglycemic coma (blood glucose ≤3.9 mmol/L) within 1 month prior to screening;
- •Patients intolerant to renal puncture/intrarenal injection procedures;
- •Patients with diagnosis of acute kidney injury, congenital or hereditary kidney diseases, renal atrophy, or other renal conditions deemed ineligible by the investigator, as well as patients with a history of kidney transplantation at screening;
- •Presence of severe systemic diseases within 6 months prior to screening and judged by the investigator as unsuitable for the study;
- •Patients requiring long-term anticoagulant or antiplatelet therapy who, in the investigator's judgment, cannot discontinue medication 1 week prior to renal puncture/intrarenal injection procedures;
- •Patients with suicidal risk, history of psychiatric disorders, or history of epilepsy at screening;
- •Patients with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;
- •Patients participated in other clinical trials with interventions within 1 month prior to screening;
- •Subject with assessed survival time of less than 1 year by investigators at screening;
- •Investigators, co-investigators, study coordinators, employees of participating investigators or research centers, or family members of the above individuals;
- •Any condition that, in the investigator's judgment, may increase subject risk or interfere with the clinical trial.
研究组 & 干预措施
REGEND003
Experimental
REGEND003 for dosage escalation
干预措施: REGEND003 (Biological)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
Adverse Event (AE) associated with the Cell Therapy
时间窗: Within 24 weeks post-treatment
The incidence and severity of adverse events will be evaluated.
次要结局
- Complications associated with Intrarenal Injection(Within 24 weeks post-treatment)
- Change from Baseline in Concentration of C-Reactive Protein(Within 24 weeks post-treatment)
- Change from Baseline in Glomerular Filtration Rate (GFR)(Within 24 weeks post-treatment)
- Change from Baseline in Concentration of Serum Creatinine(Within 24 weeks post-treatment)
- Change from Baseline in 24-Hour Urinary Protein Excretion(Within 24 weeks post-treatment)
- Change from Baseline in Urine Albumin-Creatinine Ratio (uACR)(Within 24 weeks post-treatment)
- Change from Baseline in Kidney Volume(Winthin 24 weeks post-treatment)
- Change from Baseline in Renal Cortical Thickness (RCT)(Within 24 weeks post-treatment)
- Changes from Baseline in the Outcomes from Kidney Disease Quality of Life (KDQOL) Survey(Within 24 weeks post-treatment)
- Change from Baseline in Blood Pressure(Within 24 weeks post-treatment)
- Time from Injection to First Kidney Disease Progression (KDP)(Within 24 weekd post-treatment)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
早期 1 期
Cell-based Therapy for the Treatment of Kidney DiseaseKidney DiseasesNCT04187625Brigham and Women's Hospital10
招募中
不适用
ational PROspective infrastructure for Renal Cell Carcinomakidney cancer10038364renal cell carcinomaNL-OMON56090Stichting PRO-RCC10,000
已完成
3 期
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxKidney Transplantation in Highly Sensitized PatientsNCT04935177Hansa Biopharma AB64
招募中
3 期
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Renal Cell CarcinomaNCT07227402Merck Sharp & Dohme LLC904
撤回
1 期
NOMINATE/ Minimisation of Immunosuppression in Kidney TransplantationRenal Transplant RejectionRenal Transplant InfectionNCT05073822University College, London